CTRI/2015/07/006043招募中3 期
A Clinical Study to evaluate the Efficacy , Safety and Tolerability of Brinzolamide 1.0% w/v plus Brimonidine Tartrate 0.2 % w/v Ophthalmic Suspension Vs. Brinzolamide 1% eye drops in patients with Open-Angle Glaucoma or Ocular Hypertension
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 232
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •A clinical diagnosis of glaucoma or Ocular hypertension at least in at one (study) eye.
- •IOP between 21 to less tnan and equal 36 mm of Hg.
- •Freshly diagnosed patients of open angle glaucoma or ocular hypertension, Patients who are previously diagnosed and on treatment for open angle glaucoma or ocular hypertension will undergo washout period, Miotics (7 days), Alpha Agonist and Alpha/beta agonist (14 days), β antagonist and prostaglandin analogs (21 days).
- •Subject with H/O discontinued Carbonic anhydrase inhibitor since past 4 months.
- •Voluntary willingness to give written informed consent prior to participation in trial.
排除标准
- •Any history of:
- •Ocular trauma or intraocular surgery within the past 6 months;
- •Ocular infection, inflammation, or laser surgery within the past 3 months;
- •Any present observation of:
- •Chronic, recurrent or severe inflammatory eye disease.
- •Central cornea thickness 620 mm, as measured by pachymetry, in either eye.
- •Shaffer angle grade less than 2 in either eye (range, 0 [complete or partial closure] to 3 [wide open angle, more than 20]), as measured by Gonioscopy.
- •Severe central visual field loss in either eye measured by Perimetry.
- •Clinically significant or progressive retinal disease.
- •Best-corrected visual acuity worse than 0.6 logMAR (Best Corrected VA score worse than 55 ETDRS letters (20/80 Snellen equivalent).
- •Other ocular pathology (including severe dry eye) that may preclude the administration of an alpha-adrenergic agonist and/or a topical CAI.
- •Patients with broken rear lens capsule or anterior eye lenses or in patients with known risk factors for cystoid macular edema or iritis / uveitis.
- •Patients who are required to wear contact lens during the study period.
- •Cup/disc ratio greater than 0.80.
研究者
相似试验
已完成
不适用
A Clinical Study to Evaluate the Efficacy, Safety and Consumer Perception of a Moisturizing Productsensitive skinJPRN-UMIN000047956ION CORPORATIO35
招募中
1 期
Evaluate The Efficacy And Safety Of HMTG-122106 In ChildreCTRI/2023/07/054858Himalaya Wellness Company
尚未招募
3 期
Result of Psorlyn tablet and Psorlyn oil in Psoriasis(skin disease).CTRI/2021/04/033243DrVasishths Ayuremedies
尚未招募
1 期
To Evaluate The Efficacy And Safety Of HSGM-122104 Inchildren in (Healthy Human Volunteers)CTRI/2023/07/054999Himalaya Wellness Company
尚未招募
4 期
To study the effect of Panchakarma Essential (Nirgundi-based formulation) in Knee Osteoarthritis.CTRI/2023/07/055689Mprex Healthcare Pvt. Ltd.
